MOSS-THINK: Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue

Sponsor

RenJi Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05778110

Collaborator

(none)

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The goal of this experimental observation study is to figure out differently expressed biomarkers in lesion tissues in traumatic brain injury or hypertension intracranial hemorrhage patients. The main questions it aims to answer is:

Which RNA, protein and metabolites are differently expressed in lesion tissues?
What molecular mechanism is participated in TBI or ICH? Participants will be treated by emergency operation, and their lesion tissues will be collected during the operation.

Condition or Disease	Intervention/Treatment	Phase
Brain Injury Traumatic Severe Intracranial Hemorrhage, Hypertensive	Other: Type of disease

Study Design

Study Type:

Observational

Anticipated Enrollment :

10 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

Multiomic Analysis of Traumatic Brain Injury and Hypertension Intracranial Hemorrhage Lesion Tissue

Anticipated Study Start Date :

Apr 1, 2023

Anticipated Primary Completion Date :

Mar 31, 2024

Anticipated Study Completion Date :

Dec 31, 2024

Arms and Interventions

Arm	Intervention/Treatment
TBI Patients with traumatic brain injury.	Other: Type of disease Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.
ICH Patients with hypertensive intracranial hemorrhage.	Other: Type of disease Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.

Arm

Intervention/Treatment

TBI

Patients with traumatic brain injury.

Other: Type of disease

Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.

ICH

Patients with hypertensive intracranial hemorrhage.

Other: Type of disease

Different types of pathogen: brain injury by trauma or intracranial hemorrhage due to hypertension.

Outcome Measures

Primary Outcome Measures

RNA biomarkers in TBI or ICH patients' lesion tissues assessed by transcriptome bioinformatic analysis [Immediately after collecting tissues]
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through transcriptome sequencing. The results of transcriptome sequencing will be further analyzed by bioinformatic analysis to reveal different RNA expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Protein biomarkers in TBI or ICH patients' lesion tissues assessed by proteomic bioinformatic analysis [Immediately after collecting tissues]
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through proteomics mass spectrometry. The results of proteomic will be further analyzed by bioinformatic analysis to reveal different protein expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.
Metabolite biomarkers in TBI or ICH patients' lesion tissues assessed by metabolomic bioinformatic analysis [Immediately after collecting tissues]
Patients' lesion tissue will be collected during hematoma evacuation. Then these tissues will be immediately prepared to be detected through metabolomic mass spectrometry. The results of metabolomic will be further analyzed by bioinformatic analysis to reveal different metabolite expressions in lesion tissues of severe TBI and ICH patients as the potential biomarkers.

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age >18 and <65
Within 12 hours after brain injury
GCS ≥3 and ≤8
Closed brain injury with frontotemporal contusion or basal ganglia intracranial hemorrhage
Need emergency intracranial hematoma evacuating operation
Patient's agents are informed and consent the research